A phase II study of the PI3K inhibitor copanlisib in combination with the anti-CD20 monoclonal antibody rituximab for patients with marginal zone lymphoma: treatment rationale and protocol design of the COUP-1 trial

Peer Review reports

Original Submission
28 Jul 2020	Submitted	Original manuscript
24 Sep 2020	Reviewed	Reviewer Report
27 Sep 2020	Reviewed	Reviewer Report
3 Dec 2020	Reviewed	Reviewer Report
24 Dec 2020	Author responded	Author comments - Alexander Grunenberg
Resubmission - Version 2
24 Dec 2020	Submitted	Manuscript version 2
24 Mar 2021	Reviewed	Reviewer Report
1 May 2021	Author responded	Author comments - Alexander Grunenberg
Resubmission - Version 3
1 May 2021	Submitted	Manuscript version 3
Publishing
9 Jun 2021	Editorially accepted
29 Jun 2021	Article published	10.1186/s12885-021-08464-6

Back to article page